Vapotherm to Report Fourth Quarter and Fiscal Year 2019 Financial Results
February 19 2020 - 04:02PM
Business Wire
Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a
global medical technology company focused on the development and
commercialization of its proprietary Hi-VNI® Technology products
that are used to treat patients of all ages suffering from
respiratory distress, today announced that it will release
financial results for the fourth quarter and fiscal year 2019 after
the close of trading on Wednesday, March 4, 2020. Vapotherm’s
management team will host a conference call beginning at 4:30 p.m.
ET to discuss the financial results and recent business
developments.
To listen to the conference call on your telephone, please dial
(877) 201-0168 for U.S. callers, or (647) 788-4901 for
international callers, approximately ten minutes prior to start
time and reference conference code 9050486. To listen to a live
webcast, please visit the Investors section of the Vapotherm
website at:
http://investors.vapotherm.com/events-and-presentations/events. The
webcast replay will be available on the Vapotherm website for 90
days following the completion of the call. A replay of this
conference call will be available over the phone through March 11,
2020 by dialing (800) 585-8367 in the U.S. or (416) 621-4642
outside of the U.S. The replay access code is 9050486.
Vapotherm, Inc. (NYSE: VAPO) is a publicly traded
developer and manufacturer of advanced respiratory technology based
in Exeter, New Hampshire, USA. The company develops innovative,
comfortable, non-invasive technologies for respiratory support of
patients with chronic or acute breathing disorders. Over 2.0
million patients have been treated with Vapotherm Hi-VNI
Technology. For more information, visit www.vapotherm.com.
Hi-VNI® Technology is mask-free noninvasive ventilation
for spontaneously breathing patients and a front-line tool for
relieving respiratory distress—including hypercapnia, hypoxemia,
and dyspnea. It allows for the fast, safe treatment of
undifferentiated respiratory distress with one user-friendly tool.
Hi-VNI Technology’s mask-free interface delivers optimally
conditioned breathing gases, making it comfortable for patients and
reducing the risks and care complexities associated with mask
therapies. While being treated, patients can talk, eat, drink and
take oral medication.
Website Information Vapotherm routinely posts important
information for investors on the Investor Relations section of its
website, http://investors.vapotherm.com/. Vapotherm intends to use
this website as a means of disclosing material, non-public
information and for complying with Vapotherm’s disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the Investor Relations section of Vapotherm’s website, in
addition to following Vapotherm’s press releases, Securities and
Exchange Commission filings, public conference calls, presentations
and webcasts. The information contained on, or that may be accessed
through, Vapotherm’s website is not incorporated by reference into,
and is not a part of, this document.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200219005703/en/
Investor Relations Contact: Mark Klausner or Mike Vallie
Westwicke, an ICR Company ir@vtherm.com +1-(603)-658-0011
Vapotherm (NYSE:VAPO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Vapotherm (NYSE:VAPO)
Historical Stock Chart
From Mar 2023 to Mar 2024